| Predicate | Object |
|---|---|
| rdf:type | |
| biopax3:comment |
FUNCTION: Inhibits translation initiation and cap-dependent translation. May excert its function by hindering the interaction between EIF4A1 and EIF4G. Inhibits the helicase activity of EIF4A. Modulates the activation of JUN kinase. Down-regulates the expression of MAP4K1, thus inhibiting events important in driving invasion, namely, MAPK85 activation and consequent JUN-dependent transcription. May play a role in apoptosis. Tumor suppressor. Inhibits tumor promoter-induced neoplastic transformation. Binds RNA (By similarity). SUBUNIT: Interacts (via MI domains) with EIF4A2 (By similarity). Interacts (via MI domains) with EIF4A1 (via N-terminal domain). Heterotrimer with EIF4A1; one molecule of PDCD4 binds two molecules of EIF4A1. Interacts with EIF4G1. May form a complex with EIF4A1 and EIF4G1. The interaction between PDCD4 and EIF4A1 interferes with the interaction between EIF4A1 and EIF4G. When phosphorylated, interacts with BTRC and FBXW11. SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Shuttles between the nucleus and cytoplasm. Predominantly nuclear under normal growth conditions, and when phosphorylated at Ser-457. Exported from the nucleus in the absence of serum. TISSUE SPECIFICITY: Up-regulated in proliferative cells. Highly expressed in epithelial cells of the mammary gland. Reduced expression in lung cancer and colon carcinoma. INDUCTION: IL2/interleukin-2 stimulation inhibits expression, while IL12/interleukin-12 increases expression. DOMAIN: Binds EIF4A1 via both MI domains. PTM: Polyubiquitinated, leading to its proteasomal degradation. Rapidly degraded in response to mitogens. Phosphorylation of the phosphodegron promotes interaction with BTRC and proteasomal degradation. PTM: Phosphorylated at Ser-67 by RPS6KB1 in response to mitogens; phosphorylation promotes proteasomal degradation of PDCD4. SIMILARITY: Belongs to the PDCD4 family. SIMILARITY: Contains 2 MI domains. SEQUENCE CAUTION: Sequence=AAB42218.1; Type=Erroneous gene model prediction; Sequence=AAH15036.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence; WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/PDCD4ID41675ch10q24.html"; GENE SYNONYMS:PDCD4 H731. COPYRIGHT: Protein annotation is derived from the UniProt Consortium (http://www.uniprot.org/). Distributed under the Creative Commons Attribution-NoDerivs License.,
SEQUENCE 469 AA; 51735 MW; 2CAE1D2055491177 CRC64;
|
| biopax3:xref |
urn:biopax:RelationshipXref:HGNC_HGNC:8763,
urn:biopax:RelationshipXref:NCBI GENE_27250,
urn:biopax:RelationshipXref:REFSEQ_NP_055271,
urn:biopax:UnificationXref:UNIPROT_O15501,
urn:biopax:UnificationXref:UNIPROT_Q53EL6,
urn:biopax:UnificationXref:UNIPROT_Q5VZS6,
urn:biopax:UnificationXref:UNIPROT_Q6PJI5,
urn:biopax:UnificationXref:UNIPROT_Q8TAR5,
urn:biopax:UnificationXref:UNIPROT_Q99834
|
| biopax3:displayName |
PDCD4_HUMAN
|
| biopax3:name |
Neoplastic transformation inhibitor protein,
Nuclear antigen H731-like,
PDCD4,
Protein 197/15a
|
| biopax3:entityFeature |
urn:biopax:ModificationFeature:PDCD4_HUMAN_1,
urn:biopax:ModificationFeature:PDCD4_HUMAN_2,
urn:biopax:ModificationFeature:PDCD4_HUMAN_3,
urn:biopax:ModificationFeature:PDCD4_HUMAN_4,
urn:biopax:ModificationFeature:PDCD4_HUMAN_5,
urn:biopax:ModificationFeature:PDCD4_HUMAN_6,
urn:biopax:ModificationFeature:PDCD4_HUMAN_7,
urn:biopax:ModificationFeature:PDCD4_HUMAN_8
|
| biopax3:organism | |
| biopax3:sequence |
MDVENEQILNVNPADPDNLSDSLFSGDEENAGTEEIKNEINGNWISASSINEARINAKAKRRLRKNSSRDSGRGDSVSDSGSDALRSGLTVPTSPKGRLLDRRSRSGKGRGLPKKGGAGGKGVWGTPGQVYDVEEVDVKDPNYDDDQENCVYETVVLPLDERAFEKTLTPIIQEYFEHGDTNEVAEMLRDLNLGEMKSGVPVLAVSLALEGKASHREMTSKLLSDLCGTVMSTTDVEKSFDKLLKDLPELALDTPRAPQLVGQFIARAVGDGILCNTYIDSYKGTVDCVQARAALDKATVLLSMSKGGKRKDSVWGSGGGQQSVNHLVKEIDMLLKEYLLSGDISEAEHCLKELEVPHFHHELVYEAIIMVLESTGESTFKMILDLLKSLWKSSTITVDQMKRGYERIYNEIPDINLDVPHSYSVLERFVEECFQAGIISKQLRDLCPSRGRKRFVSEGDGGRLKPESY
|
| biopax3:standardName |
Programmed cell death protein 4
|